{"id":37652,"date":"2024-04-15T05:29:49","date_gmt":"2024-04-15T05:29:49","guid":{"rendered":"https:\/\/edukemy.com\/blog\/?p=37652"},"modified":"2024-04-15T05:29:50","modified_gmt":"2024-04-15T05:29:50","slug":"tb-status-in-india-and-bedaquiline-patent-challenge-upsc-social-justice-notes","status":"publish","type":"post","link":"https:\/\/edukemy.com\/blog\/tb-status-in-india-and-bedaquiline-patent-challenge-upsc-social-justice-notes\/","title":{"rendered":"TB Status in India and Bedaquiline Patent Challenge – UPSC Social Justice Notes"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Tuberculosis (TB) remains a significant public health challenge in India, representing one of the highest burdens of the disease globally. Despite extensive efforts to control it, TB continues to affect millions, particularly among vulnerable populations. In recent years, the emergence of drug-resistant strains has further complicated treatment strategies. In the midst of this crisis, the issue of access to effective medications has come to the forefront, with the patent challenge against Bedaquiline\u2014a crucial drug in the fight against multidrug-resistant TB\u2014highlighting the tension between pharmaceutical patents and public health priorities. This challenge underscores the need for innovative approaches to ensure equitable access to life-saving treatments for all individuals affected by TB in India and beyond.<\/p>\n\n\n\n

\n